A new mixed-methods study of 23 cancer survivors found that most participants felt little direct stigma around cannabis use for symptom management. However, fear of being judged for opioid use emerged as a surprisingly powerful force steering some patients toward cannabis, raising important questions about how stigma shapes treatment decisions in oncology care.

Cancer survivors manage complex symptom burdens with an expanding menu of options, including cannabis, opioids, and conventional adjuvants. How patients weigh those options is not purely pharmacological; stigma plays an underrecognized role in what patients try, what they disclose, and what they avoid. If opioid stigma is silently redirecting treatment decisions in oncology, clinicians who are unaware of this dynamic may be missing critical context when patients present with undertreated pain or unexplained cannabis use. Understanding the stigma landscape is a precondition for honest, shared decision-making.

Cannabis use among cancer patients has risen steadily alongside broader societal normalization, yet the role of stigma in shaping whether survivors adopt or avoid cannabis remains poorly characterized. This 2026 study used a convergent parallel mixed-methods design, combining the Recreational and Medical Cannabis Attitudes Scale (RMCAS) with six virtual focus groups, to explore stigma experiences among 23 cancer survivors drawn from a parent observational study (NCT06037681). Ten participants were active cannabis users, and thirteen were non-users. The qualitative analysis was grounded in Andersen’s four-component stigma framework, supplemented by inductive coding for emergent themes. The study deliberately recruited from both user and non-user groups to capture a broader attitudinal spectrum than prior cannabis-focused research typically achieves.

Quantitatively, participants held generally positive attitudes toward cannabis. Qualitatively, explicit cannabis stigma was not a dominant theme; most survivors felt comfortable with their cannabis decisions and perceived little judgment from peers. The most striking emergent finding was the prominence of opioid-related stigma, both perceived from society at large and internalized by patients themselves, which appeared to influence some survivors to choose cannabis over opioids. Notably, despite overall acceptance, some participants still withheld cannabis use from their providers, suggesting latent disclosure barriers persist. The authors acknowledge that the sample of 23 from a narrow geographic region limits generalizability, that some focus groups fell below target size (as small as two participants), and that formal inter-rater reliability metrics were not reported. They position these findings as hypothesis-generating, calling for larger, more diverse studies to quantify the relationship between opioid stigma and cannabis uptake in oncology.

What this study gets right is naming something many of us observe in clinic but rarely see addressed in the literature: the opioid crisis narrative has become so powerful that patients are sometimes more afraid of being seen as “an opioid user” than they are of uncontrolled pain. That fear is real, and it does not always lead to the best clinical decisions. I appreciate that this team captured it in a structured way. At the same time, 23 participants from one region, with focus groups as small as two people, means we are looking at texture and pattern, not prevalence or causation. This is a conversation starter, not a conclusion.

In my own practice, I ask every patient about both cannabis and opioid experiences, and I ask about the feelings that come with each. The number of patients who tell me they would rather use cannabis “because at least nobody looks at you funny” is significant. I take that seriously, but I also make sure patients understand that avoiding a well-indicated medication because of stigma is itself a harm. The goal is always to match the intervention to the symptom, not to the social pressure.

This study sits at an early exploratory stage in a research arc that has largely focused on barriers to cannabis access or attitudes among providers rather than examining the comparative stigma landscape across analgesic categories from the patient perspective. For clinicians, the most actionable insight is not about cannabis per se but about the hidden dynamics influencing what patients choose to disclose. If opioid stigma is steering patients away from appropriate pain management and toward cannabis as a default alternative, providers who do not proactively create space for non-judgmental discussion may unknowingly reinforce suboptimal care patterns.

From a pharmacological standpoint, cannabis and opioids occupy very different efficacy profiles for cancer pain; substituting one for the other based on stigma rather than clinical evidence introduces real risk of undertreated pain. Drug interaction considerations also apply, as cannabinoids can modulate cytochrome P450 pathways relevant to opioid metabolism. The finding that some patients conceal cannabis use from providers compounds this concern. One concrete recommendation: oncology teams should routinely and explicitly ask about cannabis use in the same normalized tone used for over-the-counter supplements, framing it as standard medication reconciliation rather than a values inquiry.